(Q39716312)

14 September 2017

1 reference

title

The clinical pharmacology of methotrexate: new applications of an old drug (English)

1 reference

14 September 2017

The clinical pharmacology of methotrexate.new applications of an old drug (English)

1 reference

10.1002/1097-0142(197801)41:1<36::AID-CNCR2820410108>3.0.CO;2-I

https://api.crossref.org/works/10.1002/1097-0142(197801)41:1%3C36::AID-CNCR2820410108%3E3.0.CO;2-I

31 March 2023

1 reference

1 reference

1 reference

10.1002/1097-0142(197801)41:1<36::AID-CNCR2820410108>3.0.CO;2-I

https://api.crossref.org/works/10.1002/1097-0142(197801)41:1%3C36::AID-CNCR2820410108%3E3.0.CO;2-I

31 March 2023

author name string

W. A. Bleyer

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A342086

31 March 2023

language of work or name

English

0 references

publication date

1 January 1978

1 reference

full work available at URL

14 September 2017

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2F1097-0142(197801)41:1%3C36::AID-CNCR2820410108%3E3.0.CO;2-I

1 reference

10.1002/1097-0142(197801)41:1<36::AID-CNCR2820410108>3.0.CO;2-I

https://api.crossref.org/works/10.1002/1097-0142(197801)41:1%3C36::AID-CNCR2820410108%3E3.0.CO;2-I

https://onlinelibrary.wiley.com/doi/full/10.1002/1097-0142(197801)41:1%3C36::AID-CNCR2820410108%3E3.0.CO;2-I

31 March 2023

1 reference

10.1002/1097-0142(197801)41:1<36::AID-CNCR2820410108>3.0.CO;2-I

https://api.crossref.org/works/10.1002/1097-0142(197801)41:1%3C36::AID-CNCR2820410108%3E3.0.CO;2-I

31 March 2023

1 reference

14 September 2017

41

1 reference

14 September 2017

1

1 reference

14 September 2017

36-51

1 reference

Computed tomographic appearance of methotrexate-induced necrotizing leukoencephalopathy

14 September 2017

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%28197801%2941%3A1%3C36%3A%3AAID-CNCR2820410108%3E3.0.CO%3B2-I

Methotrexate therapy of Wegener's granulomatosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%28197801%2941%3A1%3C36%3A%3AAID-CNCR2820410108%3E3.0.CO%3B2-I

Methotrexate in Liver and Bile after Intravenous Dosage in Man

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%28197801%2941%3A1%3C36%3A%3AAID-CNCR2820410108%3E3.0.CO%3B2-I

The variability of individual tolerance to methotrexate in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%28197801%2941%3A1%3C36%3A%3AAID-CNCR2820410108%3E3.0.CO%3B2-I

Necrotizing Encephalopath Following Intraventricular Instillatio of Methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%28197801%2941%3A1%3C36%3A%3AAID-CNCR2820410108%3E3.0.CO%3B2-I

21 January 2018

2

30

1344

Anderson

1970

1 reference

10.1002/1097-0142(197801)41:1<36::AID-CNCR2820410108>3.0.CO;2-I

https://api.crossref.org/works/10.1002/1097-0142(197801)41:1%3C36::AID-CNCR2820410108%3E3.0.CO;2-I

Methyltetrahydrofolic acid mediates N- and O-methylation of biogenic amines.

31 March 2023

4

1 reference

10.1002/1097-0142(197801)41:1<36::AID-CNCR2820410108>3.0.CO;2-I

https://api.crossref.org/works/10.1002/1097-0142(197801)41:1%3C36::AID-CNCR2820410108%3E3.0.CO;2-I

Immunologic Suppression by Methotrexate in Dermatology

31 March 2023

5

1 reference

10.1002/1097-0142(197801)41:1<36::AID-CNCR2820410108>3.0.CO;2-I

https://api.crossref.org/works/10.1002/1097-0142(197801)41:1%3C36::AID-CNCR2820410108%3E3.0.CO;2-I

31 March 2023

6

35

1305

Bender

1975

1 reference

10.1002/1097-0142(197801)41:1<36::AID-CNCR2820410108>3.0.CO;2-I

https://api.crossref.org/works/10.1002/1097-0142(197801)41:1%3C36::AID-CNCR2820410108%3E3.0.CO;2-I

31 March 2023

7

30

2372

Bertino

1970

1 reference

10.1002/1097-0142(197801)41:1<36::AID-CNCR2820410108>3.0.CO;2-I

https://api.crossref.org/works/10.1002/1097-0142(197801)41:1%3C36::AID-CNCR2820410108%3E3.0.CO;2-I

Increased Level of Dihydrofolic Reductase in Leucocytes of Patients Treated with Amethopterin

31 March 2023

8

1 reference

10.1002/1097-0142(197801)41:1<36::AID-CNCR2820410108>3.0.CO;2-I

https://api.crossref.org/works/10.1002/1097-0142(197801)41:1%3C36::AID-CNCR2820410108%3E3.0.CO;2-I

31 March 2023

Cancer Treatment Reports

11

61

1419

Bleyer

1977

1 reference

10.1002/1097-0142(197801)41:1<36::AID-CNCR2820410108>3.0.CO;2-I

https://api.crossref.org/works/10.1002/1097-0142(197801)41:1%3C36::AID-CNCR2820410108%3E3.0.CO;2-I

Methotrexate: clinical pharmacology, current status and therapeutic guidelines

31 March 2023

13

1 reference

10.1002/1097-0142(197801)41:1<36::AID-CNCR2820410108>3.0.CO;2-I

https://api.crossref.org/works/10.1002/1097-0142(197801)41:1%3C36::AID-CNCR2820410108%3E3.0.CO;2-I

Neurotoxicity and Elevated Cerebrospinal-Fluid Methotrexate Concentration in Meningeal Leukemia

31 March 2023

15

1 reference

10.1002/1097-0142(197801)41:1<36::AID-CNCR2820410108>3.0.CO;2-I

https://api.crossref.org/works/10.1002/1097-0142(197801)41:1%3C36::AID-CNCR2820410108%3E3.0.CO;2-I

31 March 2023

17

35

110

Bourke

1975

1 reference

10.1002/1097-0142(197801)41:1<36::AID-CNCR2820410108>3.0.CO;2-I

https://api.crossref.org/works/10.1002/1097-0142(197801)41:1%3C36::AID-CNCR2820410108%3E3.0.CO;2-I

31 March 2023

19

35

801

Bruckner

1975

1 reference

10.1002/1097-0142(197801)41:1<36::AID-CNCR2820410108>3.0.CO;2-I

https://api.crossref.org/works/10.1002/1097-0142(197801)41:1%3C36::AID-CNCR2820410108%3E3.0.CO;2-I

Long-term remissions following one and two-dose chemotherapy for African lymphoma

31 March 2023

20

1 reference

10.1002/1097-0142(197801)41:1<36::AID-CNCR2820410108>3.0.CO;2-I

https://api.crossref.org/works/10.1002/1097-0142(197801)41:1%3C36::AID-CNCR2820410108%3E3.0.CO;2-I

Enzymatic cleavage of methotrexate provides a method for prevention of drug toxicity

31 March 2023

23

1 reference

10.1002/1097-0142(197801)41:1<36::AID-CNCR2820410108>3.0.CO;2-I

https://api.crossref.org/works/10.1002/1097-0142(197801)41:1%3C36::AID-CNCR2820410108%3E3.0.CO;2-I

Threshold Methotrexate Concentration for In Vivo Inhibition of DNA Synthesis in Normal and Tumorous Target Tissues

31 March 2023

24

1 reference

10.1002/1097-0142(197801)41:1<36::AID-CNCR2820410108>3.0.CO;2-I

https://api.crossref.org/works/10.1002/1097-0142(197801)41:1%3C36::AID-CNCR2820410108%3E3.0.CO;2-I

Effect of oral prophylactic broad spectrum nonabsorbable antibiotics on the gastrointestinal absorption of nutrients and methotrexate in small cell bronchogenic carcinoma patients

31 March 2023

27

1 reference

10.1002/1097-0142(197801)41:1<36::AID-CNCR2820410108>3.0.CO;2-I

https://api.crossref.org/works/10.1002/1097-0142(197801)41:1%3C36::AID-CNCR2820410108%3E3.0.CO;2-I

Site of action of methotrexate in psoriasis

31 March 2023

28

1 reference

10.1002/1097-0142(197801)41:1<36::AID-CNCR2820410108>3.0.CO;2-I

https://api.crossref.org/works/10.1002/1097-0142(197801)41:1%3C36::AID-CNCR2820410108%3E3.0.CO;2-I

Renal toxicity of methotrexate

31 March 2023

29

1 reference

10.1002/1097-0142(197801)41:1<36::AID-CNCR2820410108>3.0.CO;2-I

https://api.crossref.org/works/10.1002/1097-0142(197801)41:1%3C36::AID-CNCR2820410108%3E3.0.CO;2-I

Failure of leucovorin rescue to prevent reactivation of a solar burn after high dose methotrexate

31 March 2023

30

1 reference

10.1002/1097-0142(197801)41:1<36::AID-CNCR2820410108>3.0.CO;2-I

https://api.crossref.org/works/10.1002/1097-0142(197801)41:1%3C36::AID-CNCR2820410108%3E3.0.CO;2-I

31 March 2023

33

27

2561

Djerassi

1967

1 reference

10.1002/1097-0142(197801)41:1<36::AID-CNCR2820410108>3.0.CO;2-I

https://api.crossref.org/works/10.1002/1097-0142(197801)41:1%3C36::AID-CNCR2820410108%3E3.0.CO;2-I

Methotrexate and citrovorum factor rescue in the management of childhood lymphosarcoma and reticulum cell sarcoma (non-Hodgkin's lymphomas): parolonged unmaintained remissions

31 March 2023

35

1 reference

10.1002/1097-0142(197801)41:1<36::AID-CNCR2820410108>3.0.CO;2-I

https://api.crossref.org/works/10.1002/1097-0142(197801)41:1%3C36::AID-CNCR2820410108%3E3.0.CO;2-I

Phase I study of high doses of methotrexate with citrovorum factor in patients with lung cancer

31 March 2023

37

1 reference

10.1002/1097-0142(197801)41:1<36::AID-CNCR2820410108>3.0.CO;2-I

https://api.crossref.org/works/10.1002/1097-0142(197801)41:1%3C36::AID-CNCR2820410108%3E3.0.CO;2-I

Irradiation, methotrexate toxicity, and the treatment of meningeal leukaemia

31 March 2023

38

1 reference

10.1002/1097-0142(197801)41:1<36::AID-CNCR2820410108>3.0.CO;2-I

https://api.crossref.org/works/10.1002/1097-0142(197801)41:1%3C36::AID-CNCR2820410108%3E3.0.CO;2-I

Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid

31 March 2023

41

1 reference

10.1002/1097-0142(197801)41:1<36::AID-CNCR2820410108>3.0.CO;2-I

https://api.crossref.org/works/10.1002/1097-0142(197801)41:1%3C36::AID-CNCR2820410108%3E3.0.CO;2-I

Intracerebral calcifications appearing during the course of acute lymphocytic leukemia treated with methotrexate and X-rays

31 March 2023

42

1 reference

10.1002/1097-0142(197801)41:1<36::AID-CNCR2820410108>3.0.CO;2-I

https://api.crossref.org/works/10.1002/1097-0142(197801)41:1%3C36::AID-CNCR2820410108%3E3.0.CO;2-I

31 March 2023

Methotrexate revisited

43

1 reference

10.1002/1097-0142(197801)41:1<36::AID-CNCR2820410108>3.0.CO;2-I

https://api.crossref.org/works/10.1002/1097-0142(197801)41:1%3C36::AID-CNCR2820410108%3E3.0.CO;2-I

New approaches to cancer chemotherapy with methotrexate

31 March 2023

44

1 reference

10.1002/1097-0142(197801)41:1<36::AID-CNCR2820410108>3.0.CO;2-I

https://api.crossref.org/works/10.1002/1097-0142(197801)41:1%3C36::AID-CNCR2820410108%3E3.0.CO;2-I

Topical Methotrexate in Psoriasis

31 March 2023

45

1 reference

10.1002/1097-0142(197801)41:1<36::AID-CNCR2820410108>3.0.CO;2-I

https://api.crossref.org/works/10.1002/1097-0142(197801)41:1%3C36::AID-CNCR2820410108%3E3.0.CO;2-I

Leukoencephalopathy following chemotherapy for rhabdomyosarcoma: reversibility of cerebral changes demonstrated by computed tomography

31 March 2023

46

1 reference

10.1002/1097-0142(197801)41:1<36::AID-CNCR2820410108>3.0.CO;2-I

https://api.crossref.org/works/10.1002/1097-0142(197801)41:1%3C36::AID-CNCR2820410108%3E3.0.CO;2-I

Paraplegia following intrathecal methotrexate: report of a case and review of the literature

31 March 2023

47

1 reference

10.1002/1097-0142(197801)41:1<36::AID-CNCR2820410108>3.0.CO;2-I

https://api.crossref.org/works/10.1002/1097-0142(197801)41:1%3C36::AID-CNCR2820410108%3E3.0.CO;2-I

Methotrexate toxicity: Correlation with duration of administration, plasma levels, dose and excretion pattern

31 March 2023

49

1 reference

10.1002/1097-0142(197801)41:1<36::AID-CNCR2820410108>3.0.CO;2-I

https://api.crossref.org/works/10.1002/1097-0142(197801)41:1%3C36::AID-CNCR2820410108%3E3.0.CO;2-I

The characteristics of the membrane transport of amethopterin and the naturally occurring folates

31 March 2023

50

1 reference

10.1002/1097-0142(197801)41:1<36::AID-CNCR2820410108>3.0.CO;2-I

https://api.crossref.org/works/10.1002/1097-0142(197801)41:1%3C36::AID-CNCR2820410108%3E3.0.CO;2-I

31 March 2023

Molecular Pharmacology

51

10

257

Goldman

1974

1 reference

10.1002/1097-0142(197801)41:1<36::AID-CNCR2820410108>3.0.CO;2-I

https://api.crossref.org/works/10.1002/1097-0142(197801)41:1%3C36::AID-CNCR2820410108%3E3.0.CO;2-I

31 March 2023

Molecular Pharmacology

52

10

275

Goldman

1974

1 reference

10.1002/1097-0142(197801)41:1<36::AID-CNCR2820410108>3.0.CO;2-I

https://api.crossref.org/works/10.1002/1097-0142(197801)41:1%3C36::AID-CNCR2820410108%3E3.0.CO;2-I

31 March 2023

54

25

1018

Henderson

1965

1 reference

10.1002/1097-0142(197801)41:1<36::AID-CNCR2820410108>3.0.CO;2-I

https://api.crossref.org/works/10.1002/1097-0142(197801)41:1%3C36::AID-CNCR2820410108%3E3.0.CO;2-I

Parenchymatous degeneration of the central nervous system in childhood leukemia

31 March 2023

55

1 reference

10.1002/1097-0142(197801)41:1<36::AID-CNCR2820410108>3.0.CO;2-I

https://api.crossref.org/works/10.1002/1097-0142(197801)41:1%3C36::AID-CNCR2820410108%3E3.0.CO;2-I

Unbalanced Deoxyribonucleotide Synthesis Caused by Methotrexate

31 March 2023

57

1 reference

10.1002/1097-0142(197801)41:1<36::AID-CNCR2820410108>3.0.CO;2-I

https://api.crossref.org/works/10.1002/1097-0142(197801)41:1%3C36::AID-CNCR2820410108%3E3.0.CO;2-I

Treatment of leukemia with large doses of methotrexate and folinic acid: clinical-biochemical correlates

31 March 2023

59

1 reference

10.1002/1097-0142(197801)41:1<36::AID-CNCR2820410108>3.0.CO;2-I

https://api.crossref.org/works/10.1002/1097-0142(197801)41:1%3C36::AID-CNCR2820410108%3E3.0.CO;2-I

Pharmacokinetics of methotrexate

31 March 2023

60

1 reference

10.1002/1097-0142(197801)41:1<36::AID-CNCR2820410108>3.0.CO;2-I

https://api.crossref.org/works/10.1002/1097-0142(197801)41:1%3C36::AID-CNCR2820410108%3E3.0.CO;2-I

High dose methotrexate therapy of solid tumors: observations relating to clinical toxicity

31 March 2023

62

1 reference

10.1002/1097-0142(197801)41:1<36::AID-CNCR2820410108>3.0.CO;2-I

https://api.crossref.org/works/10.1002/1097-0142(197801)41:1%3C36::AID-CNCR2820410108%3E3.0.CO;2-I

Adjuvant methotrexate and citrovorum-factor treatment of osteogenic sarcoma

31 March 2023

68

1 reference

10.1002/1097-0142(197801)41:1<36::AID-CNCR2820410108>3.0.CO;2-I

https://api.crossref.org/works/10.1002/1097-0142(197801)41:1%3C36::AID-CNCR2820410108%3E3.0.CO;2-I

Weekly high-dose methotrexate-citrovorum factor in osteogenic sarcoma.Pre-surgical treatment of primary tumor and of overt pulmonary metastases

31 March 2023

69

1 reference

10.1002/1097-0142(197801)41:1<36::AID-CNCR2820410108>3.0.CO;2-I

https://api.crossref.org/works/10.1002/1097-0142(197801)41:1%3C36::AID-CNCR2820410108%3E3.0.CO;2-I

Encephalopathy in acute leukaemia associated with methotrexate therapy

31 March 2023

74

1 reference

10.1002/1097-0142(197801)41:1<36::AID-CNCR2820410108>3.0.CO;2-I

https://api.crossref.org/works/10.1002/1097-0142(197801)41:1%3C36::AID-CNCR2820410108%3E3.0.CO;2-I

31 March 2023

75

28

564

Kessel

1968

1 reference

10.1002/1097-0142(197801)41:1<36::AID-CNCR2820410108>3.0.CO;2-I

https://api.crossref.org/works/10.1002/1097-0142(197801)41:1%3C36::AID-CNCR2820410108%3E3.0.CO;2-I

Induction of remission in acute leukemia of childhood by combination of prednisone and either 6-mercaptopurine or methotrexate

31 March 2023

79

1 reference

10.1002/1097-0142(197801)41:1<36::AID-CNCR2820410108>3.0.CO;2-I

https://api.crossref.org/works/10.1002/1097-0142(197801)41:1%3C36::AID-CNCR2820410108%3E3.0.CO;2-I

Spontaneous Remission or Response to Methotrexate in Sarcoidosis

31 March 2023

80

1 reference

10.1002/1097-0142(197801)41:1<36::AID-CNCR2820410108>3.0.CO;2-I

https://api.crossref.org/works/10.1002/1097-0142(197801)41:1%3C36::AID-CNCR2820410108%3E3.0.CO;2-I

N-Methylation of Dopamine to Epinine in Brain Tissue using N-Methyltetrahydrofolic Acid as the Methyl Donor

31 March 2023

81

1 reference

10.1002/1097-0142(197801)41:1<36::AID-CNCR2820410108>3.0.CO;2-I

https://api.crossref.org/works/10.1002/1097-0142(197801)41:1%3C36::AID-CNCR2820410108%3E3.0.CO;2-I

31 March 2023

84

33

1729

Levitt

1973

1 reference

10.1002/1097-0142(197801)41:1<36::AID-CNCR2820410108>3.0.CO;2-I

https://api.crossref.org/works/10.1002/1097-0142(197801)41:1%3C36::AID-CNCR2820410108%3E3.0.CO;2-I

The effect of organic acids on renal clearance of methotrexate in man

31 March 2023

85

1 reference

10.1002/1097-0142(197801)41:1<36::AID-CNCR2820410108>3.0.CO;2-I

https://api.crossref.org/works/10.1002/1097-0142(197801)41:1%3C36::AID-CNCR2820410108%3E3.0.CO;2-I

The synergistic effect of salicylates on methotrexate toxicity

31 March 2023

88

1 reference

10.1002/1097-0142(197801)41:1<36::AID-CNCR2820410108>3.0.CO;2-I

https://api.crossref.org/works/10.1002/1097-0142(197801)41:1%3C36::AID-CNCR2820410108%3E3.0.CO;2-I

Cell kinetics and practical consequences for therapy of acute leukemia

31 March 2023

89

1 reference

10.1002/1097-0142(197801)41:1<36::AID-CNCR2820410108>3.0.CO;2-I

https://api.crossref.org/works/10.1002/1097-0142(197801)41:1%3C36::AID-CNCR2820410108%3E3.0.CO;2-I

Effect of lipid-soluble esters of methotrexate on DNA synthesis in human skin.

31 March 2023

90

1 reference

10.1002/1097-0142(197801)41:1<36::AID-CNCR2820410108>3.0.CO;2-I

https://api.crossref.org/works/10.1002/1097-0142(197801)41:1%3C36::AID-CNCR2820410108%3E3.0.CO;2-I

Parenteral methotrexate in psoriasis. A report on the efficacy and toxicity of long-term intermittent treatment

31 March 2023

91

1 reference

10.1002/1097-0142(197801)41:1<36::AID-CNCR2820410108>3.0.CO;2-I

https://api.crossref.org/works/10.1002/1097-0142(197801)41:1%3C36::AID-CNCR2820410108%3E3.0.CO;2-I

Methotrexate hepatotoxicity in children with leukemia

31 March 2023

92

1 reference

10.1002/1097-0142(197801)41:1<36::AID-CNCR2820410108>3.0.CO;2-I

https://api.crossref.org/works/10.1002/1097-0142(197801)41:1%3C36::AID-CNCR2820410108%3E3.0.CO;2-I

Effects of chemotherapy on the central nervous system. A study of parenteral methotrexate in long-term survivors of leukemia and lymphoma in childhood

31 March 2023

93

1 reference

10.1002/1097-0142(197801)41:1<36::AID-CNCR2820410108>3.0.CO;2-I

https://api.crossref.org/works/10.1002/1097-0142(197801)41:1%3C36::AID-CNCR2820410108%3E3.0.CO;2-I

Polymyositis and Dermatomyositis: Combined Methotrexate and Corticosteroid Therapy

31 March 2023

94

1 reference

10.1002/1097-0142(197801)41:1<36::AID-CNCR2820410108>3.0.CO;2-I

https://api.crossref.org/works/10.1002/1097-0142(197801)41:1%3C36::AID-CNCR2820410108%3E3.0.CO;2-I

Immunosuppressive Effects of Cytosine Arabinoside and Methotrexate in Man

31 March 2023

95

1 reference

10.1002/1097-0142(197801)41:1<36::AID-CNCR2820410108>3.0.CO;2-I

https://api.crossref.org/works/10.1002/1097-0142(197801)41:1%3C36::AID-CNCR2820410108%3E3.0.CO;2-I

31 March 2023

Methotrexate meningitis

96

1 reference

10.1002/1097-0142(197801)41:1<36::AID-CNCR2820410108>3.0.CO;2-I

https://api.crossref.org/works/10.1002/1097-0142(197801)41:1%3C36::AID-CNCR2820410108%3E3.0.CO;2-I

The pharmacokinetics of cyclophosphamide in man following treatment with methotrexate

31 March 2023

97

1 reference

10.1002/1097-0142(197801)41:1<36::AID-CNCR2820410108>3.0.CO;2-I

https://api.crossref.org/works/10.1002/1097-0142(197801)41:1%3C36::AID-CNCR2820410108%3E3.0.CO;2-I

Acute and chronic effects of methotrexate on hepatic, pulmonary, and skeletal systems

31 March 2023

98

1 reference

10.1002/1097-0142(197801)41:1<36::AID-CNCR2820410108>3.0.CO;2-I

https://api.crossref.org/works/10.1002/1097-0142(197801)41:1%3C36::AID-CNCR2820410108%3E3.0.CO;2-I

Leukoencephalopathy following the administration of methotrexate into the cerebrospinal fluid in the treatment of primary brain tumors

31 March 2023

101

1 reference

10.1002/1097-0142(197801)41:1<36::AID-CNCR2820410108>3.0.CO;2-I

https://api.crossref.org/works/10.1002/1097-0142(197801)41:1%3C36::AID-CNCR2820410108%3E3.0.CO;2-I

Reversible dementia temporally associated with intraventricular therapy with methotrexate in a child with acute myelogenous leukemia

31 March 2023

107

1 reference

10.1002/1097-0142(197801)41:1<36::AID-CNCR2820410108>3.0.CO;2-I

https://api.crossref.org/works/10.1002/1097-0142(197801)41:1%3C36::AID-CNCR2820410108%3E3.0.CO;2-I

31 March 2023

108

48

787

Podurgiel

1973

1 reference

10.1002/1097-0142(197801)41:1<36::AID-CNCR2820410108>3.0.CO;2-I

https://api.crossref.org/works/10.1002/1097-0142(197801)41:1%3C36::AID-CNCR2820410108%3E3.0.CO;2-I

31 March 2023

109

37

1982

Poplack

1977

1 reference

10.1002/1097-0142(197801)41:1<36::AID-CNCR2820410108>3.0.CO;2-I

https://api.crossref.org/works/10.1002/1097-0142(197801)41:1%3C36::AID-CNCR2820410108%3E3.0.CO;2-I

The central nervous system in childhood leukemia.II. Subacute leukoencephalopathy

31 March 2023

111

1 reference

10.1002/1097-0142(197801)41:1<36::AID-CNCR2820410108>3.0.CO;2-I

https://api.crossref.org/works/10.1002/1097-0142(197801)41:1%3C36::AID-CNCR2820410108%3E3.0.CO;2-I

Pontine glioma. High-dose methotrexate and leucovorin rescue.

31 March 2023

117

1 reference

10.1002/1097-0142(197801)41:1<36::AID-CNCR2820410108>3.0.CO;2-I

https://api.crossref.org/works/10.1002/1097-0142(197801)41:1%3C36::AID-CNCR2820410108%3E3.0.CO;2-I

Disseminated necrotizing leukoencephalopathy: a complication of treated central nervous system leukemia and lymphoma

31 March 2023

118

1 reference

10.1002/1097-0142(197801)41:1<36::AID-CNCR2820410108>3.0.CO;2-I

https://api.crossref.org/works/10.1002/1097-0142(197801)41:1%3C36::AID-CNCR2820410108%3E3.0.CO;2-I

Methotrexate: distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections

31 March 2023

124

1 reference

10.1002/1097-0142(197801)41:1<36::AID-CNCR2820410108>3.0.CO;2-I

https://api.crossref.org/works/10.1002/1097-0142(197801)41:1%3C36::AID-CNCR2820410108%3E3.0.CO;2-I

Brain damage after intrathecal methotrexate

31 March 2023

125

1 reference

10.1002/1097-0142(197801)41:1<36::AID-CNCR2820410108>3.0.CO;2-I

https://api.crossref.org/works/10.1002/1097-0142(197801)41:1%3C36::AID-CNCR2820410108%3E3.0.CO;2-I

Methotrexate-induced pneumonitis

31 March 2023

126

1 reference

10.1002/1097-0142(197801)41:1<36::AID-CNCR2820410108>3.0.CO;2-I

https://api.crossref.org/works/10.1002/1097-0142(197801)41:1%3C36::AID-CNCR2820410108%3E3.0.CO;2-I

The effect of amethopterin on the immune response

31 March 2023

131

1 reference

10.1002/1097-0142(197801)41:1<36::AID-CNCR2820410108>3.0.CO;2-I

https://api.crossref.org/works/10.1002/1097-0142(197801)41:1%3C36::AID-CNCR2820410108%3E3.0.CO;2-I

Studies of the metabolism of methotrexate by intestinal flora. I. Identification and study of biological properties of the metabolite 4-amino-4-deoxy-N 10 -methylpteroic acid

31 March 2023

133

1 reference

10.1002/1097-0142(197801)41:1<36::AID-CNCR2820410108>3.0.CO;2-I

https://api.crossref.org/works/10.1002/1097-0142(197801)41:1%3C36::AID-CNCR2820410108%3E3.0.CO;2-I

31 March 2023

Cancer Treatment Reports

134

61

745

Von Hoff

1977

1 reference

10.1002/1097-0142(197801)41:1<36::AID-CNCR2820410108>3.0.CO;2-I

https://api.crossref.org/works/10.1002/1097-0142(197801)41:1%3C36::AID-CNCR2820410108%3E3.0.CO;2-I

31 March 2023

136

34

3487

Wan

1974

1 reference

10.1002/1097-0142(197801)41:1<36::AID-CNCR2820410108>3.0.CO;2-I

https://api.crossref.org/works/10.1002/1097-0142(197801)41:1%3C36::AID-CNCR2820410108%3E3.0.CO;2-I

31 March 2023

137

36

1441

Wang

1976

1 reference

10.1002/1097-0142(197801)41:1<36::AID-CNCR2820410108>3.0.CO;2-I

https://api.crossref.org/works/10.1002/1097-0142(197801)41:1%3C36::AID-CNCR2820410108%3E3.0.CO;2-I

Scabies norvegica. Treatment with methotrexate

31 March 2023

140

1 reference

10.1002/1097-0142(197801)41:1<36::AID-CNCR2820410108>3.0.CO;2-I

https://api.crossref.org/works/10.1002/1097-0142(197801)41:1%3C36::AID-CNCR2820410108%3E3.0.CO;2-I

Biochemical and pathophysiological rationale for amethopterin in psoriasis

31 March 2023

143

1 reference

10.1002/1097-0142(197801)41:1<36::AID-CNCR2820410108>3.0.CO;2-I

https://api.crossref.org/works/10.1002/1097-0142(197801)41:1%3C36::AID-CNCR2820410108%3E3.0.CO;2-I

31 March 2023

Methotrexate

144

1 reference

10.1002/1097-0142(197801)41:1<36::AID-CNCR2820410108>3.0.CO;2-I

https://api.crossref.org/works/10.1002/1097-0142(197801)41:1%3C36::AID-CNCR2820410108%3E3.0.CO;2-I

Neurotoxicity of commonly used antineoplastic agents (first of two parts).

31 March 2023

145

1 reference

10.1002/1097-0142(197801)41:1<36::AID-CNCR2820410108>3.0.CO;2-I

https://api.crossref.org/works/10.1002/1097-0142(197801)41:1%3C36::AID-CNCR2820410108%3E3.0.CO;2-I

31 March 2023

Molecular Pharmacology

146

11

287

White

1975

1 reference

10.1002/1097-0142(197801)41:1<36::AID-CNCR2820410108>3.0.CO;2-I

https://api.crossref.org/works/10.1002/1097-0142(197801)41:1%3C36::AID-CNCR2820410108%3E3.0.CO;2-I

Journal of Clinical Investigation

31 March 2023

148

52

92a

Young

1973

1 reference

10.1002/1097-0142(197801)41:1<36::AID-CNCR2820410108>3.0.CO;2-I

https://api.crossref.org/works/10.1002/1097-0142(197801)41:1%3C36::AID-CNCR2820410108%3E3.0.CO;2-I

The New England Journal of Medicine

31 March 2023

151

294

52

Zweig

1976

1 reference

10.1002/1097-0142(197801)41:1<36::AID-CNCR2820410108>3.0.CO;2-I

https://api.crossref.org/works/10.1002/1097-0142(197801)41:1%3C36::AID-CNCR2820410108%3E3.0.CO;2-I

31 March 2023

Identifiers

10.1002/1097-0142(197801)41:1<36::AID-CNCR2820410108>3.0.CO;2-I

1 reference

14 September 2017

1 reference